Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Ecopetrol
EC
$35B
| $156M | 0.12% |
7,826,786
+784,180
| +11% | +$14.5M |
|
177
Portland General Electric
POR
$5.69B
| $156M | 0.12% |
2,792,328
+187,900
| +7% | +$10.5M |
|
178
Gold Fields
GFI
$36B
| $155M | 0.12% |
23,505,612
+275,312
| +1% | +$1.56M |
|
179
RTX Corp
RTX
$302B
| $155M | 0.12% |
1,642,246
-211,337
| -11% | -$19.2M |
|
180
Toyota
TM
$225B
| $153M | 0.12% |
1,090,010
-126,798
| -10% | -$17.7M |
|
181
DexCom
DXCM
$33.8B
| $153M | 0.12% |
2,800,972
+2,579,372
| +1,164% | +$122M |
|
|
HTZ
182
DELISTED
Hertz Global Holdings, Inc.
HTZ
| $152M | 0.12% |
9,657,583
+2,329,775
| +32% | +$34.9M |
|
183
AXIS Capital
AXS
$7.35B
| $152M | 0.12% |
2,557,030
-149,500
| -6% | -$9.04M |
|
184
PepsiCo
PEP
$189B
| $152M | 0.12% |
1,109,726
-1,916,110
| -63% | -$261M |
|
185
Pan American Silver
PAAS
$21.8B
| $150M | 0.12% |
6,344,252
-1,575,962
| -20% | -$29.2M |
|
186
Best Buy
BBY
$17.6B
| $147M | 0.11% |
1,670,830
-80,800
| -5% | -$6.18M |
|
187
HEICO Corp Class A
HEI.A
$37B
| $146M | 0.11% |
1,635,852
-172,300
| -10% | -$16.4M |
|
188
Dolby
DLB
$5.75B
| $145M | 0.11% |
2,114,557
-298,443
| -12% | -$19.7M |
|
|
SNP
189
DELISTED
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
| $145M | 0.11% |
2,415,804
+327,201
| +16% | +$19M |
|
190
Televisa
TV
$1.48B
| $145M | 0.11% |
12,382,734
+1,024,076
| +9% | +$11.3M |
|
191
Sprouts Farmers Market
SFM
$7.87B
| $145M | 0.11% |
7,477,220
+607,720
| +9% | +$11.8M |
|
192
JetBlue
JBLU
$2.19B
| $144M | 0.11% |
7,716,604
-1,671,400
| -18% | -$31.1M |
|
193
Marathon Petroleum
MPC
$94.5B
| $144M | 0.11% |
+2,392,199
| New | +$150M |
|
|
PPL
194
PPL Corp
PPL
$26.5B
| $143M | 0.11% |
3,978,421
-1,756,799
| -31% | -$58.9M |
|
195
Acuity Brands
AYI
$10.7B
| $141M | 0.11% |
1,023,116
+114,116
| +13% | +$14.7M |
|
196
Vistra
VST
$48.6B
| $141M | 0.11% |
6,116,699
+3,840,426
| +169% | +$99.1M |
|
197
B2Gold
BTG
$6.7B
| $140M | 0.11% |
34,965,055
+803,164
| +2% | +$2.83M |
|
|
PINC
198
DELISTED
Premier
PINC
| $139M | 0.11% |
3,680,209
+107,600
| +3% | +$3.79M |
|
199
UBS Group
UBS
$176B
| $138M | 0.11% |
10,961,100
+1,606,600
| +17% | +$19.1M |
|
200
Aecom
ACM
$8.62B
| $137M | 0.11% |
3,179,477
+1,568,200
| +97% | +$65M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.